1-4 of 4
Willem W. Overwijk
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

Willem W. Overwijk, Marc R. Theoret, Steven E. Finkelstein, Deborah R. Surman, Laurina A. de Jong, Florry A. Vyth-Dreese, Trees A. Dellemijn, Paul A. Antony, Paul J. Spiess, Douglas C. Palmer, David M. Heimann, Christopher A. Klebanoff, Zhiya Yu, Leroy N. Hwang, Lionel Feigenbaum, Ada M. Kruisbeek, Steven A. Rosenberg, Nicholas P. Restifo
Journal: Journal of Experimental Medicine
J Exp Med (2003) 198 (4): 569–580.
https://doi.org/10.1084/jem.20030590
Published: 18 August 2003
View article titled, Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8<sup>+</sup> T Cells
Open the PDF for Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8<sup>+</sup> T Cells in another window
Journal Articles

Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine: Comparison of Prophylaxis and Therapy

In Special Collection:
2018 Nobel Prize Collection
Andrea van Elsas, Roger P.M. Sutmuller, Arthur A. Hurwitz, Jennifer Ziskin, Jennifer Villasenor, Jan-Paul Medema, Willem W. Overwijk, Nicholas P. Restifo, Cornelis J.M. Melief, Rienk Offringa, James P. Allison
Journal: Journal of Experimental Medicine
J Exp Med (2001) 194 (4): 481–490.
https://doi.org/10.1084/jem.194.4.481
Published: 20 August 2001
View article titled, Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine: <subtitle>Comparison of Prophylaxis and Therapy</subtitle>
Open the PDF for Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine: <subtitle>Comparison of Prophylaxis and Therapy</subtitle> in another window
Journal Articles

Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen: Implications for Tumor Immunotherapy

Teresa A. Colella, Timothy N.J. Bullock, Liane B. Russell, David W. Mullins, Willem W. Overwijk, Chance John Luckey, Richard A. Pierce, Nicholas P. Restifo, Victor H. Engelhard
Journal: Journal of Experimental Medicine
J Exp Med (2000) 191 (7): 1221–1232.
https://doi.org/10.1084/jem.191.7.1221
Published: 03 April 2000
View article titled, Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen: <subtitle>Implications for Tumor Immunotherapy</subtitle>
Open the PDF for Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen: <subtitle>Implications for Tumor Immunotherapy</subtitle> in another window
Journal Articles

gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

Willem W. Overwijk, Allan Tsung, Kari R. Irvine, Maria R. Parkhurst, Theresa J. Goletz, Kangla Tsung, Miles W. Carroll, Chunlei Liu, Bernard Moss, Steven A. Rosenberg, Nicholas P. Restifo
Journal: Journal of Experimental Medicine
J Exp Med (1998) 188 (2): 277–286.
https://doi.org/10.1084/jem.188.2.277
Published: 20 July 1998
View article titled, gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand
Open the PDF for gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand in another window